AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+16.34%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$645M
AUM Growth
+$645M
(+1.5%)
Cap. Flow
-$54.3M
Cap. Flow
% of AUM
-8.43%
Top 10 Holdings %
Top 10 Hldgs %
44.28%
Holding
108
New
9
Increased
21
Reduced
28
Closed
17
Top Buys
| 1 |
Nuvalent
NUVL
|
$14.1M |
| 2 |
Alkermes
ALKS
|
$9.8M |
| 3 |
Viridian Therapeutics
VRDN
|
$8.53M |
| 4 |
Wave Life Sciences
WVE
|
$8.41M |
| 5 |
ORKA
Oruka Therapeutics, Inc. Common Stock
ORKA
|
$6.8M |
Top Sells
Sector Composition
| 1 | Healthcare | 92.7% |
| 2 | Financials | 0.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Xenon Pharmaceuticals
XENE
$2.98B
| $45M | 6.15% | 1,144,021 +149,794 | +15% | +$5.9M |
|
2
Apogee Therapeutics
APGE
$2.17B
| $39M | 5.32% | 664,198 -172,085 | -21% | -$10.1M |
|
|
3
Nuvalent
NUVL
$5.52B
| $34.5M | 4.71% | 337,500 +137,500 | +69% | +$14.1M |
|
4
Arcellx
ACLX
$3.85B
| $33.4M | 4.56% | 400,000 -60,000 | -13% | -$5.01M |
|
|
5
Alkermes
ALKS
$4.78B
| $28M | 3.82% | 1,000,000 +350,000 | +54% | +$9.8M |
|
6
Teva Pharmaceuticals
TEVA
$21.1B
| $25.2M | 3.44% | 1,400,000 -50,000 | -3% | -$901K |
|
7
Madrigal Pharmaceuticals
MDGL
$9.76B
| $21.2M | 2.9% | 100,000 -10,000 | -9% | -$2.12M |
|
8
Crinetics Pharmaceuticals
CRNX
$2.92B
| $20.4M | 2.79% | 400,000 -115,000 | -22% | -$5.88M |
|
9
Nurix Therapeutics
NRIX
$714M
| $19.3M | 2.64% | 860,399 -51,601 | -6% | -$1.16M |
|
10
Vera Therapeutics
VERA
$1.38B
| $19.2M | 2.62% | 435,000 +60,000 | +16% | +$2.65M |
|
|
VRNA
11
Verona Pharma
VRNA
$9.16B
| $18.7M | 2.55% | 650,000 -50,000 | -7% | -$1.44M |
|
|
AUTL
12
Autolus Therapeutics
AUTL
$399M
| $16.3M | 2.23% | 4,500,000 +200,000 | +5% | +$726K |
|
|
CNTA
13
Centessa Pharmaceuticals
CNTA
$2.25B
| $15.4M | 2.11% | 965,612 -170,090 | -15% | -$2.72M |
|
|
INZY
14
DELISTED
Inozyme Pharma
INZY
| $14.8M | 2.01% | 2,822,318 -33,934 | -1% | -$177K |
|
15
Spyre Therapeutics
SYRE
$996M
| $14.7M | 2% | 498,420 -15,000 | -3% | -$441K |
|
16
Kura Oncology
KURA
$686M
| $13.4M | 1.83% | 687,785 +37,785 | +6% | +$738K |
|
17
Establishment Labs
ESTA
$1.2B
| $12.6M | 1.72% | 290,447 +67,040 | +30% | +$2.9M |
|
|
18
Viridian Therapeutics
VRDN
$1.5B
| $11.9M | 1.63% | 525,000 +375,000 | +250% | +$8.53M |
|
|
19
Wave Life Sciences
WVE
$1.53B
| $11.5M | 1.57% | 1,400,000 +1,025,000 | +273% | +$8.41M |
|
|
ORKA
20
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $8.57M | 1.17% | 349,836 +277,352 | +383% | +$6.8M |
|
21
Rezolute
RZLT
$619M
| $8.25M | 1.13% | 1,700,000 -150,000 | -8% | -$728K |
|
22
Merus
MRUS
$4.98B
| $8.08M | 1.1% | 161,741 +36,741 | +29% | +$1.84M |
|
23
Astria Therapeutics
ATXS
$349M
| $7.98M | 1.09% | 725,106 -250,500 | -26% | -$2.76M |
|
|
ONC
24
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $7.86M | 1.07% | 35,000 -75,000 | -68% | -$16.8M |
|
25
NewAmsterdam Pharma
NAMS
$2.71B
| $7.84M | 1.07% | 472,390 +49,235 | +12% | +$817K |
|